What is more, this therapeutic implication was the solution to infiltrating the dilemma of CAR-T cells as they demonstrated the ability to transport them to the tumor site and maintain HER-2-CAR-T cells at low levels for nearly two months. Here, ERBB2 is linked to neoplasm.